Is EGF receptor–tyrosine kinase inhibitor therapy in non-small-cell lung cancer patients with EGFR mutations the best option?

By Hayashi Hidetoshi   Nakagawa Kazuhiko  

Lung Cancer Management, Vol. 2, Iss. 6, 2013-12 ,pp. : 441-443

Future Medicine

Access to resources Recommend Favorite

Effect and mechanism of Src tyrosine kinase inhibitor sunitinib on the drug-resistance reversal of human A549/DDP cisplatin-resistant lung cancer cell line

By      

Molecular Medicine Reports, Vol. 10, Iss. 4, 2014-01 ,pp. : 2065-2072

Spandidos Publications

Access to resources Recommend Favorite

Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies

By Carrera S.   Buque A.   Azkona E.   Aresti U.   Calvo B.   Sancho A.   Arruti M.   Nuño M.   Rubio I.   Lobera A.   Lopez C.   Vivanco G.  

Clinical and Translational Oncology, Vol. 16, Iss. 4, 2014-04 ,pp. : 339-350

Springer Publishing Company

Access to resources Recommend Favorite

Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer

By        

Oncology Reports, Vol. 27, Iss. 6, 2012-01 ,pp. : 2066-2072

Spandidos Publications

Access to resources Recommend Favorite

Muscarinic receptor stimulation increases tolerance of rat salivary gland function to radiation damage

By Coppes R. P.   Vissink A.   Zeilstra L. J. W.   Konings A. W. T.  

International Journal of Radiation Biology, Vol. 72, Iss. 5, 1997-11 ,pp. : 615-625

Informa Healthcare

Access to resources Recommend Favorite